Mark J. Foley - Oct 13, 2022 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role: CEO, Director
Signature: /s/ Dwight Moxie, Attorney-in-Fact
Stock symbol: RVNC
Transactions as of: Oct 13, 2022
Transactions value $: -$1,328,920
Form type: 4
Date filed: 10/14/2022, 07:02 PM
Previous filing: Mar 9, 2023
Next filing: Jan 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Tax liability	-$1.33M	-49.3K	-6.43%	$26.97	717K	Oct 13, 2022	Direct	F1
holding	RVNC	Common Stock						111K	Oct 13, 2022	See footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares withheld by and surrendered to the Issuer on October 13, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock awards ("RSA's") for 400,000 shares. The RSA's vest in three equal annual installments from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
F2	These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.

Content

Represents the number of shares withheld by and surrendered to the Issuer on October 13, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock awards ("RSA's") for 400,000 shares. The RSA's vest in three equal annual installments from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.

These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.